FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207112> ?p ?o ?g. }

• W4387207112 endingPage "e422" @default.
• W4387207112 startingPage "e422" @default.
• W4387207112 abstract "Published data supports the use of very high dose intensity modulated radiotherapy (IMRT) in achieving high efficacy and low toxicity for high-risk prostate cancer (HRPCa). This phase II multi-institutional non-randomized prospective dose escalation study using intensity modulated radiotherapy (IMRT) for high risk N0M0 prostate cancer was designed to investigate dose escalation using 1.8 Gy increments from baseline 75.6 Gy up to maximum 81 Gy, once dose volume constraints were adhered to.Inclusion criteria were patients undergoing a radical course of RT for high and very high-risk disease, defined as one or more of the criteria ≥ T3*, ≥ Gleason 8, Prostate specific antigen (PSA) > 20ng/ml. All patients received Androgen Deprivation Therapy (ADT) and none had radiological evidence of distant metastatic disease. The primary objective was to determine if dose escalated IMRT for high risk localized prostate cancer could provide freedom from biochemical relapse (BR; PSA rising > nadir +2ng/mL or initiation of salvage hormone therapy) similar to that reported in the literature. The Kaplan-Meier method was used to estimate survival times. Secondary objectives included OS, Disease Free Survival (DFS), and the incidence and severity of Genito-urinary (GU), Gastro-intestinal (GI) and erectile dysfunction (ED) toxicities (CTCAE v.3). Toxicities and performance status were collected and graded weekly during RT, 2 months after completing RT, 8 months' post RT, and 6 monthly thereafter to year five and annually thereafter to year nine.A total of 230 evaluable patients were enrolled between April 2009 and June 2016. The median follow-up was 7.3 years. The cumulative proportion of patients surviving without BR at 5 years was 91% (95% Confidence Interval (CI): 86% to 94%). Overall survival at 5 and 7 years was 92% (88% to 95%) and 89% (83% to 92%) respectively, while the cumulative proportion of patients free from disease was 89% (84% to 93%) at 5 years and 81% (75% to 86%) at 7 years. The incidence of acute G2 and G3 toxicities were; GU; 57.8% G2, 12.6% G3, GI; 15.2% G2, 0.4% G3, ED; 30.0% G2 and 61.7% G3. The incidence of late G2, G3 and G4 toxicities were; GU; 40.9% G2, 8.7% G3, GI; 36.5% G2, 2.2% G3, 0.4% G4, ED; 11.7% G2 and 86.1% G3. The percentage of patients receiving each dose level was; 3.5% received 75.6Gy in 42 fractions, 2.2% received 77.4Gy in 43 fractions, 93% received 81Gy in 45 fractions.The findings indicate that high-dose IMRT is well tolerated and is associated with excellent long-term tumor-control outcomes in patients with localized high and very high-risk prostate cancer, with 91% of patients surviving at 5 years without biochemical relapse. The rates of long term G3 GU and GI toxicity were low at 8.7% and 0.4% respectively." @default.
• W4387207112 created "2023-09-30" @default.
• W4387207112 creator A5002048877 @default.
• W4387207112 creator A5007041913 @default.
• W4387207112 creator A5009871905 @default.
• W4387207112 creator A5012170307 @default.
• W4387207112 creator A5014093898 @default.
• W4387207112 creator A5019676747 @default.
• W4387207112 creator A5020976081 @default.
• W4387207112 creator A5021113834 @default.
• W4387207112 creator A5022823856 @default.
• W4387207112 creator A5029130301 @default.
• W4387207112 creator A5041904375 @default.
• W4387207112 creator A5042560472 @default.
• W4387207112 creator A5045610877 @default.
• W4387207112 creator A5050252131 @default.
• W4387207112 creator A5069771417 @default.
• W4387207112 creator A5071535693 @default.
• W4387207112 creator A5071766104 @default.
• W4387207112 creator A5081855614 @default.
• W4387207112 creator A5085444959 @default.
• W4387207112 creator A5092972749 @default.
• W4387207112 date "2023-10-01" @default.
• W4387207112 modified "2023-10-17" @default.
• W4387207112 title "A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0M0 Prostate Cancer" @default.
• W4387207112 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1578" @default.
• W4387207112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785387" @default.
• W4387207112 hasPublicationYear "2023" @default.
• W4387207112 type Work @default.
• W4387207112 citedByCount "0" @default.
• W4387207112 crossrefType "journal-article" @default.
• W4387207112 hasAuthorship W4387207112A5002048877 @default.
• W4387207112 hasAuthorship W4387207112A5007041913 @default.
• W4387207112 hasAuthorship W4387207112A5009871905 @default.
• W4387207112 hasAuthorship W4387207112A5012170307 @default.
• W4387207112 hasAuthorship W4387207112A5014093898 @default.
• W4387207112 hasAuthorship W4387207112A5019676747 @default.
• W4387207112 hasAuthorship W4387207112A5020976081 @default.
• W4387207112 hasAuthorship W4387207112A5021113834 @default.
• W4387207112 hasAuthorship W4387207112A5022823856 @default.
• W4387207112 hasAuthorship W4387207112A5029130301 @default.
• W4387207112 hasAuthorship W4387207112A5041904375 @default.
• W4387207112 hasAuthorship W4387207112A5042560472 @default.
• W4387207112 hasAuthorship W4387207112A5045610877 @default.
• W4387207112 hasAuthorship W4387207112A5050252131 @default.
• W4387207112 hasAuthorship W4387207112A5069771417 @default.
• W4387207112 hasAuthorship W4387207112A5071535693 @default.
• W4387207112 hasAuthorship W4387207112A5071766104 @default.
• W4387207112 hasAuthorship W4387207112A5081855614 @default.
• W4387207112 hasAuthorship W4387207112A5085444959 @default.
• W4387207112 hasAuthorship W4387207112A5092972749 @default.
• W4387207112 hasConcept C121608353 @default.
• W4387207112 hasConcept C126322002 @default.
• W4387207112 hasConcept C126894567 @default.
• W4387207112 hasConcept C143998085 @default.
• W4387207112 hasConcept C188816634 @default.
• W4387207112 hasConcept C2776235491 @default.
• W4387207112 hasConcept C2776694085 @default.
• W4387207112 hasConcept C2777899217 @default.
• W4387207112 hasConcept C2780192828 @default.
• W4387207112 hasConcept C2780775027 @default.
• W4387207112 hasConcept C2781406297 @default.
• W4387207112 hasConcept C509974204 @default.
• W4387207112 hasConcept C71924100 @default.
• W4387207112 hasConceptScore W4387207112C121608353 @default.
• W4387207112 hasConceptScore W4387207112C126322002 @default.
• W4387207112 hasConceptScore W4387207112C126894567 @default.
• W4387207112 hasConceptScore W4387207112C143998085 @default.
• W4387207112 hasConceptScore W4387207112C188816634 @default.
• W4387207112 hasConceptScore W4387207112C2776235491 @default.
• W4387207112 hasConceptScore W4387207112C2776694085 @default.
• W4387207112 hasConceptScore W4387207112C2777899217 @default.
• W4387207112 hasConceptScore W4387207112C2780192828 @default.
• W4387207112 hasConceptScore W4387207112C2780775027 @default.
• W4387207112 hasConceptScore W4387207112C2781406297 @default.
• W4387207112 hasConceptScore W4387207112C509974204 @default.
• W4387207112 hasConceptScore W4387207112C71924100 @default.
• W4387207112 hasIssue "2" @default.
• W4387207112 hasLocation W43872071121 @default.
• W4387207112 hasLocation W43872071122 @default.
• W4387207112 hasOpenAccess W4387207112 @default.
• W4387207112 hasPrimaryLocation W43872071121 @default.
• W4387207112 hasRelatedWork W1980188241 @default.
• W4387207112 hasRelatedWork W1992657261 @default.
• W4387207112 hasRelatedWork W2038565121 @default.
• W4387207112 hasRelatedWork W2127440557 @default.
• W4387207112 hasRelatedWork W2148869351 @default.
• W4387207112 hasRelatedWork W2373651588 @default.
• W4387207112 hasRelatedWork W2897445903 @default.
• W4387207112 hasRelatedWork W3129209394 @default.
• W4387207112 hasRelatedWork W3163649103 @default.
• W4387207112 hasRelatedWork W4281788288 @default.
• W4387207112 hasVolume "117" @default.
• W4387207112 isParatext "false" @default.
• W4387207112 isRetracted "false" @default.
• W4387207112 workType "article" @default.